Skip to main content
SpringerLink
Log in

Biologika

Biologics

  • Leitthema: Meilensteine in der Rheumatologie: 75 Bände Innovation
  • Published:
Zeitschrift für Rheumatologie Aims and scope Submit manuscript

An Erratum to this article was published on 11 October 2016

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Ehrlich P (1989) Festschrift des 7. Internationalen Kongresses für Immunologie, Berlin.

  2. Köhler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256(5517):495–497

    Article  PubMed  Google Scholar 

  3. Rothe A, Power BE, Hudson PJ (2008) Therapeutic advances in rheumatology with the use of recombinant proteins. Nat Clin Pract Rheumatol 4(11):605–614

    Article  CAS  PubMed  Google Scholar 

  4. Windisch J (2015) Biosimilars versus Erstanbieterbiologika. Z Rheumatol 74(8):672–681

    Article  CAS  PubMed  Google Scholar 

  5. Dörner T, Strand V, Castañeda-Hernández G, Ferraccioli G, Isaacs JD, Kvien TK, Martin-Mola E, Mittendorf T, Smolen JS, Burmester GR (2013) The role of biosimilars in the treatment of rheumatic diseases. Ann Rheum Dis 72(3):322–328

    Article  PubMed  Google Scholar 

  6. Alten R (2015) Biosimilars in der Rheumatologie. Entwicklung und Ergebnisse klinischer Studien. Z Rheumatol 74:682–688

    Article  CAS  PubMed  Google Scholar 

  7. Vaitla PM, McDermott EM (2010) The role of high-dose intravenous immunoglobulin in rheumatology. Rheumatology (Oxford) 49(6):1040–1048

    Article  CAS  Google Scholar 

  8. Nimmerjahn F, Ravetch JV (2007) The antiinflammatory activity of IgG: the intravenous IgG paradox. J Exp Med 204(1):11–15

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Anthony RM, Ravetch JV (2010) A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs. J Clin Immunol 30(Suppl 1):S9–S14

    Article  CAS  PubMed  Google Scholar 

  10. Cantarovich D, Mauff B le, Hourmant M, Giral M, Denis M, Hirn M, Jacques Y, Soulillou JP (1989) Treatment of acute kidney rejection episodes with monoclonal antibody directed against IL2 receptor: a pilot study. Transplant Proc 21(1 Pt 2):1785–1786

    CAS  PubMed  Google Scholar 

  11. Cantarovich D, Mauff B le, Hourmant M, Giral M, Denis M, Jacques Y, Soulillou JP (1989) Anti-IL2 receptor monoclonal antibody (33B3.1) in prophylaxis of early kidney rejection in humans: a randomized trial versus rabbit antithymocyte globulin. Transplant Proc 21(1 Pt 2):1769–1771

    CAS  PubMed  Google Scholar 

  12. Herzog CH, Walker CH, Pichler W et al (1987) Monoclonal anti-CD4 in arthritis. Lancet 330:1461–1462

    Article  Google Scholar 

  13. Horneff G, Burmester GR, Emmrich F, Kalden JR (1991) Treatment of rheumatoid arthritis with an anti-CD4 monoclonal antibody. Arthritis Rheum 34(2):129–140

    Article  CAS  PubMed  Google Scholar 

  14. Horneff G, Emmrich F, Reiter C, Kalden JR, Burmester GR (1992) Persistent depletion of CD4+ T cells and inversion of the CD4/CD8 T cell ratio induced by anti-CD4 therapy. J Rheumatol 19(12):1845–1850

    CAS  PubMed  Google Scholar 

  15. Lubbe PA van der, Dijkmans BA, Markusse HM, Nässander U, Breedveld FC (1995) A randomized, double-blind, placebo-controlled study of CD4 monoclonal antibody therapy in early rheumatoid arthritis. Arthritis Rheum 38(8):1097–1106

    Article  PubMed  Google Scholar 

  16. Breedveld FC (1998) Monoclonal antibodies to CD4. Rheum Dis Clin North Am 24(3):567–578

    Article  CAS  PubMed  Google Scholar 

  17. Kremer JM, Russell AS, Emery P, Abud-Mendoza C, Szechinski J, Westhovens R, Li T, Zhou X, Becker JC, Aranda R, Peterfy C, Genant HK (2011) Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3‑year results from the AIM trial. Ann Rheum Dis 70(10):1826–1830

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, Birbara C, Box J, Natarajan K, Nuamah I, Li T, Aranda R, Hagerty DT, Dougados M (2005) Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 353(11):1114–1123 (Erratum in: (2005) N Engl J Med 353(21):2311)

    Article  CAS  PubMed  Google Scholar 

  19. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, Leeb B, Breedveld FC, Macfarlane JD, Bijl H et al (1994) Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344(8930):1105–1110

    Article  CAS  PubMed  Google Scholar 

  20. Lipsky PE, Heijde DM van der, Clair StEW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN (2000) Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N Engl J Med 343(22):1594–1602

    Article  CAS  PubMed  Google Scholar 

  21. Zink A, Manger B, Kaufmann J, Eisterhues C, Krause A, Listing J, Strangfeld A (2014) Evaluation of the RABBIT risk score for serious infections. Ann Rheum Dis 73(9):1673–1676

    Article  CAS  PubMed  Google Scholar 

  22. Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP, British Society for Rheumatology Biologics Register (2006) Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the british society for rheumatology biologics register. Arthritis Rheum 54(8):2368–2376

    Article  CAS  PubMed  Google Scholar 

  23. Chatzidionysiou K, Kristensen LE, Eriksson J, Askling J, Vollenhoven R van, ARTIS Group (2015) Effectiveness and survival-on-drug of certolizumab pegol in rheumatoid arthritis in clinical practice: results from the national Swedish register. Scand J Rheumatol 44(6):431–437

    Article  CAS  PubMed  Google Scholar 

  24. Dartel SA van, Fransen J, Kievit W, Flendrie M, Broeder AA den, Visser H, Hartkamp A, Laar MA van de, Riel PL van (2013) Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Ann Rheum Dis 72(6):895–900

    Article  PubMed  Google Scholar 

  25. Antoni C, Dechant C, Lorenz PDH-M, Wendler J, Ogilvie A, Lueftl M, Kalden-Nemeth D, Kalden JR, Manger B (2002) Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation. Arthritis Rheum 47(5):506–512

    Article  CAS  PubMed  Google Scholar 

  26. Antoni C, Krueger GG, Vlam K de, Birbara C, Beutler A, Guzzo C, Zhou B, Dooley LT, Kavanaugh A, IMPACT 2 Trial Investigators (2005) Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 64(8):1150–1157

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Mease PJ, Armstrong AW (2014) Effective management of psoriasis and psoriatic arthritis: insights on current and emerging therapies and enhanced professional collaboration. Semin Arthritis Rheum 44(3):e7–8

    Article  PubMed  Google Scholar 

  28. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, Gromnica-Ihle E, Kellner H, Krause A, Schneider M, Sörensen H, Zeidler H, Thriene W, Sieper J (2002) Treatment of active ankylosing spondylitis with infliximab: a randomized controlled multicentre trial. Lancet 359(9313):1187–1193

    Article  CAS  PubMed  Google Scholar 

  29. Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, Deodhar A, Porter B, Martin R, Andersson M, Mpofu S, Richards HB, MEASURE 1 Study Group, MEASURE 2 Study Group (2015) Secukinumab, an interleukin-17 a inhibitor, in ankylosing spondylitis. N Engl J Med 373(26):2534–2548

    Article  CAS  PubMed  Google Scholar 

  30. Bosch F van den, Deodhar A (2014) Treatment of spondyloarthritis beyond TNF-alpha blockade. Best Pract Res Clin Rheumatol 28(5):819–827. doi:10.1016/j.berh.2014.10.019.

    Article  PubMed  Google Scholar 

  31. Krieckaert CL, Jamnitski A, Nurmohamed MT, Kostense PJ, Boers M, Wolbink G (2012) Comparison of long-term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity. Arthritis Rheum 64(12):3850–3855

    Article  CAS  PubMed  Google Scholar 

  32. Mok CC, Kleij D van der, Wolbink GJ (2013) Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNFα biologics in rheumatic diseases. Clin Rheumatol 32(10):1429–1435

    Article  CAS  PubMed  Google Scholar 

  33. Vincent FB, Morand EF, Murphy K, Mackay F, Mariette X, Marcelli C (2013) Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis 72(2):165–178

    Article  CAS  PubMed  Google Scholar 

  34. Eng GP, Bouchelouche P, Bartels EM, Bliddal H, Bendtzen K, Stoltenberg M (2016) Anti-drug antibodies, drug levels, interleukin-6 and soluble TNF receptors in rheumatoid arthritis patients during the first 6 months of treatment with adalimumab or infliximab: a descriptive cohort study (in press)

  35. Zisapel M, Zisman D, Madar-Balakirski N, Arad U, Padova H, Matz H, Maman-Sarvagyl H, Kaufman I, Paran D, Feld J, Litinsky I, Wigler I, Caspi D, Elkayam O (2015) Prevalence of TNF-α blocker immunogenicity in psoriatic arthritis. J Rheumatol 42(1):73–78

    Article  CAS  PubMed  Google Scholar 

  36. Bijl AE van der, Breedveld FC, Antoni CE, Kalden JR, Kary S, Burmester GR, Beckmann C, Unnebrink K, Kupper H (2008) An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status. Clin Rheumatol 27(8):1021–1028

    Article  PubMed  PubMed Central  Google Scholar 

  37. Coates LC, Cawkwell LS, Ng NW, Bennett AN, Bryer DJ, Fraser AD, Emery P, Marzo-Ortega H (2008) Real life experience confirms sustained response to long-term biologics and switching in ankylosing spondylitis. Rheumatology (Oxford) 47(6):897–900

    Article  CAS  Google Scholar 

  38. Schiff MH, Kempis J von, Goldblum R, Tesser JR, Mueller RB (2014) Rheumatoidarthritis secondary non-responders to TNF can attain an efficacious and safe response by switching to certolizumab pegol: a phase IV, randomised, multicentre, double-blind, 12-week study, followed by a 12-week open-label phase. Ann Rheum Dis 73(12):2174–2177

    Article  CAS  PubMed  Google Scholar 

  39. Emery P, Gottenberg JE, Rubbert-Roth A, Sarzi-Puttini P, Choquette D, Taboada VM, Barile-Fabris L, Moots RJ, Ostor A, Andrianakos A, Gemmen E, Mpofu C, Chung C, Gylvin LH, Finckh A (2015) Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study. Ann Rheum Dis 74(6):979–984

    Article  CAS  PubMed  Google Scholar 

  40. Kalden JR (2015) Pathogenic cells of rheumatic inflammation as the target of modern therapies. Z Rheumatol 74:8–13

    Article  CAS  PubMed  Google Scholar 

  41. Mease PJ, Genovese MC, Greenwald MW, Ritchlin CT, Beaulieu AD, Deodhar A, Newmark R, Feng J, Erondu N, Nirula A (2014) Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. N Engl J Med 370(24):2295–2306

    Article  PubMed  Google Scholar 

  42. Genovese MC, Greenwald M, Cho CS, Berman A, Jin L, Cameron GS, Benichou O, Xie L, Braun D, Berclaz PY, Banerjee S (2014) A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors. Arthritis Rheumatol 66(7):1693–1704

    Article  CAS  PubMed  Google Scholar 

  43. Genovese MC, Durez P, Richards HB, Supronik J, Dokoupilova E, Aelion JA, Lee SH, Codding CE, Kellner H, Ikawa T, Hugot S, Ligozio G, Mpofu S (2014) One-year efficacy and safety results of secukinumab in patients with rheumatoid arthritis: phase II, dose-finding, double-blind, randomized, placebo-controlled study. J Rheumatol 41(3):414–421

    Article  CAS  PubMed  Google Scholar 

  44. Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, Deodhar A, Porter B, Martin R, Andersson M, Mpofu S, Richards HB, MEASURE 1 Study Group, MEASURE 2 Study Group (2015) Secukinumab, an interleukin-17 A inhibitor, in ankylosing spondylitis. N Engl J Med 373(26):2534–2548

    Article  CAS  PubMed  Google Scholar 

  45. Wendling D, Racadot E, Wijdenes J (1993) Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. J Rheumatol 20(2):259–262

    CAS  PubMed  Google Scholar 

  46. Genovese MC, Fleischmann R, Furst D, Janssen N, Carter J, Dasgupta B, Bryson J, Duncan B, Zhu W, Pitzalis C, Durez P, Kretsos K (2014) Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised phase IIb study. Ann Rheum Dis 73(9):1607–1615

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Smolen JS, Weinblatt ME, Sheng S, Zhuang Y, Hsu B (2014) Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2‑part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis 73(9):1616–1625

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Semerano L, Thiolat A, Minichiello E, Clavel G, Bessis N, Boissier MC (2014) Targeting IL-6 for the treatment of rheumatoid arthritis: phase II investigational drugs. Expert Opin Investig Drugs 23(7):979–999

    Article  CAS  PubMed  Google Scholar 

  49. Burmester GR, Weinblatt ME, McInnes IB, Porter D, Barbarash O, Vatutin M, Szombati I, Esfandiari E, Sleeman MA, Kane CD, Cavet G, Wang B, Godwood A, Magrini F, EARTH Study Group (2013) Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis. Ann Rheum Dis 72(9):1445–1452

    Article  CAS  PubMed  Google Scholar 

  50. Takeuchi T, Tanaka Y, Close D, Godwood A, Wu CY, Saurigny D (2015) Efficacy and safety of mavrilimumab in Japanese subjects with rheumatoid arthritis: findings from a phase IIa study. Mod Rheumatol 25(1):21–30

    Article  CAS  PubMed  Google Scholar 

  51. Shanafelt T, Lanasa MC, Call TG, Beaven AW, Leis JF, LaPlant B, Bowen D, Conte M, Jelinek DF, Hanson CA, Kay NE, Zent CS (2013) Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL). Cancer 119(21):3788–3796

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Østergaard M, Baslund B, Rigby W, Rojkovich B, Jorgensen C, Dawes PT, Wiell C, Wallace DJ, Tamer SC, Kastberg H, Petersen J, Sierakowski S (2010) Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: results of a randomized, double-blind, placebo-controlled, phase I/II study. Arthritis Rheum 62(8):2227–2238

    Article  PubMed  Google Scholar 

  53. Taylor PC, Quattrocchi E, Mallett S, Kurrasch R, Petersen J, Chang DJ (2011) Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial. Ann Rheum Dis 70(12):2119–2125

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Richez C, Truchetet ME, Schaeverbeke T, Bannwarth B (2014) Atacicept as an investigated therapy for rheumatoid arthritis. Expert Opin Investig Drugs 23(9):1285–1294

    Article  CAS  PubMed  Google Scholar 

  55. Smolen JS, Weinblatt ME, Heijde D van der, Rigby WF, Vollenhoven R van, Bingham CO 3rd, Veenhuizen M, Gill A, Zhao F, Komocsar WJ, Berclaz PY, Ortmann R, Lee C (2015) Efficacy and safety of tabalumab, an anti-B-cell-activating factor monoclonal antibody, in patients with rheumatoid arthritis who had an inadequate response to methotrexate therapy: results from a phase III multicentre, randomised, double-blind study. Ann Rheum Dis 74(8):1567–1570

    Article  CAS  PubMed  Google Scholar 

  56. Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat N, Horneff G, Brik R, McCann L, Kasapcopur O, Rutkowska-Sak L, Schneider R, Berkun Y, Calvo I, Erguven M, Goffin L, Hofer M, Kallinich T, Oliveira SK, Uziel Y, Viola S, Nistala K, Wouters C, Cimaz R, Ferrandiz MA, Flato B, Gamir ML, Kone-Paut I, Grom A, Magnusson B, Ozen S, Sztajnbok F, Lheritier K, Abrams K, Kim D, Martini A, Lovell DJ, PRINTO, PRCSG (2012) Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med 20;367(25):2396–2406

    Article  Google Scholar 

  57. Benedetti F de, Brunner HI, Ruperto N, Kenwright A, Wright S, Calvo I, Cuttica R, Ravelli A, Schneider R, Woo P, Wouters C, Xavier R, Zemel L, Baildam E, Burgos-Vargas R, Dolezalova P, Garay SM, Merino R, Joos R, Grom A, Wulffraat N, Zuber Z, Zulian F, Lovell D, Martini A, PRINTO, PRCSG (2012) Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 20;367(25):2385–2395

    Article  Google Scholar 

  58. Riethmüller G (2012) Symmetry breaking: bispecific antibodies, the beginnings, and 50 years on. Cancer Immun 12:12

    PubMed  PubMed Central  Google Scholar 

  59. Topp MS, Göckbuget N, Stein AS (2015) Safety and activity of blinatumomab for adult patients with relapsed or refractory B‑precursor acute lymphoblastic leukaemia: a multi-centre, single-arm, phase 2 study. Lancet Oncol 16(4):e158 (Correction to (2015) Lancet Oncol 16:60)

    CAS  PubMed  Google Scholar 

  60. Fischer JA, Hueber AJ, Wilson S, Galm M, Baum W, Kitson C, Auer J, Lorenz SH, Moelleken J, Bader M, Tissot AC, Tan SL, Seeber S, Schett G (2015) Combined inhibition of tumor necrosis factor α and interleukin-17 as a therapeutic opportunity in rheumatoid arthritis: development and characterization of a novel bispecific antibody. Arthritis Rheumatol 67(1):51–62

    Article  CAS  PubMed  Google Scholar 

  61. Lembke W, Schlereth B, Bertschinger J, Grabulovski DD, Locher M (2015) CVA322: A clinical stage bispecific TNF/IL-17 A inhibitor for the treatment of inflammatory diseases. Presented at Annual European Congress of Rheumatology (EULAR), Rome, Italy, 10–13 June 2015.

    Google Scholar 

  62. Caso F, Cantarini L, Lucherini OM, Sfriso P, Fioretti M, Costa L, Vitale A, Atteno M, Galeazzi M, Muscari I, Magnotti F, Frediani B, Punzi L, Rigante D (2014) Working the endless puzzle of hereditary autoinflammatory disorders. Mod Rheumatol 24(3):381–389

    Article  CAS  PubMed  Google Scholar 

  63. Ter Haar N, Lachmann H, Özen S, Woo P, Uziel Y, Modesto C, Koné-Paut I, Cantarini L, Insalaco A, Neven B, Hofer M, Rigante D, Al-Mayouf S, Touitou I, Gallizzi R, Papadopoulou-Alataki E, Martino S, Kuemmerle-Deschner J, Obici L, Iagaru N, Simon A, Nielsen S, Martini A, Ruperto N, Gattorno M, Frenkel J, Paediatric Rheumatology International Trials Organisation (PRINTO), Eurofever/Eurotraps Projects (2013) Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. Ann Rheum Dis 72(5):678–685 (May)

    Article  PubMed  Google Scholar 

  64. Zaiss MM, Frey B, Hess A, Zwerina J, Luther J, Nimmerjahn F, Engelke K, Kollias G, Hünig T, Schett G, David JP (2010) Regulatory T cells protect from local and systemic bone destruction in arthritis. J Immunol 184(12):7238–7246

    Article  CAS  PubMed  Google Scholar 

  65. Ehrenstein MR, Evans JG, Singh A, Moore S, Warnes G, Isenberg DA, Mauri C (2004) Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med 200(3):277–285

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Ellis SD, McGovern JL, Maurik A van, Howe D, Ehrenstein MR, Notley CA (2014) Induced CD8+FoxP3+ treg cells in rheumatoid arthritis are modulated by p38 phosphorylation and monocytes expressing membrane tumor necrosis factor α and CD86. Arthritis Rheumatol 66(10):2694–2705

    Article  CAS  PubMed  Google Scholar 

  67. Tabares P, Berr S, Römer PS, Chuvpilo S, Matskevich AA, Tyrsin D, Fedotov Y, Einsele H, Tony HP, Hünig T (2014) Human regulatory T cells are selectively activated by low-dose application of the CD28 superagonist TGN1412/TAB08. Eur J Immunol 44(4):1225–1236

    Article  CAS  PubMed  Google Scholar 

  68. Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, Panoskaltsis N (2006) Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355(10):1018–1028

    Article  CAS  PubMed  Google Scholar 

  69. Hünig T (2012) The storm has cleared: lessons from the CD28 superagonist TGN1412 trial. Nat Rev Immunol 12(5):317–318

    PubMed  Google Scholar 

  70. Kavanaugh A, Puig L, Gottlieb AB, Ritchlin C, You Y, Li S, Song M, Randazzo B, Rahman P, McInnes IB (2016) Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2). Ann Rheum Dis. doi:10.1136/annrheumdis-2015-209068.

    Google Scholar 

  71. Papp KA, Sundaram M, Bao Y, Williams DA, Gu Y, Signorovitch JE, Wang Y, Valdes JM, Mulani PM (2014) Effects of briakinumab treatment for moderate to severe psoriasis on health-related quality of life and work productivity and activity impairment: results from a randomized phase III study. J Eur Acad Dermatol Venereol 28(6):790–798

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Abteilung für Molekulare Immunologie, Friedrich-Alexander Universität Erlangen-Nürnberg, Nikolaus-Fiebiger-Zentrum, Glückstr. 6, 91054, Erlangen, Deutschland

    J. R. Kalden

Authors
  1. J. R. Kalden
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. R. Kalden.

Ethics declarations

Interessenkonflikt

J.R. Kalden weist auf folgende Beziehungen hin: Teilnahme an Safety Boards der Firmen GlaxoSmithKline und Sandoz; Vorträge für AbbVie.

Dieser Beitrag beinhaltet keine vom Autor durchgeführten Studien an Menschen oder Tieren.

Additional information

Redaktion

U. Müller-Ladner, Bad Nauheim

H.-M. Lorenz, Heidelberg

M. Schneider, Düsseldorf

Ein Erratum zu diesem Beitrag ist unter http://dx.doi.org/10.1007/s00393-016-0214-z zu finden.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kalden, J.R. Biologika. Z Rheumatol 75, 604–610 (2016). https://doi.org/10.1007/s00393-016-0122-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00393-016-0122-2

Search

Navigation